Good afternoon and welcome to the ADMA Biologics Second Quarter 2020 Financial Results Conference call on Wednesday, August 5, 2020. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately two hours following the end of the call. At this time, I would like to introduce Mr. Michelle Pappanastos, Managing Director at Argot Partners, ADMA's Investor Relations firm. Please go ahead.

Welcome, everyone, and thank you for joining us this afternoon to discuss ADMA Biologics' financial results for the second quarter 2020. I'm joined today by Adam Grossman, President and Chief Executive Officer, and Brian Lenz, Executive Vice President and Chief Financial Officer. During today's call, Adam will provide some introductory comments and a corporate update, and then Brian will provide an overview of the company's second quarter and six months ended June 30, 2020 financial results. Adam will then provide some brief summary remarks before opening up the call for your questions. Earlier today, we issued a press release detailing the second quarter 2020 financial results. The release is available on our website at admabiologics.com. Before we begin our formal comments, I'll remind you that we will be making forward-looking assertions during today's call that represent the company's intentions, expectations or beliefs concerning future events, which constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to factors, risks and uncertainties such as those detailed in today's press release announcing this call and in our filings with the SEC, which may cause actual results to differ materially from the results expressed or implied by such statements. In addition, any forward-looking statements represent our views only as of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update any such statements, except as required by the federal securities laws. We refer you to the disclosure notice section in our earnings release issued today and the Risk Factors section of our 2019 annual report on Form 10-K and our second quarter 2020 10-Q which we expect to file following this conference call for a discussion of important factors that could cause actual results to differ materially from these forward-looking statements. With that, I would now like to turn the call over to Adam Grossman. Adam?

Thank you, Michelle. Good afternoon, everyone. And thank you for joining us on this afternoon's call. We hope you and your families remain healthy and safe as we all continue to navigate this new world of living with COVID-19. At ADMA, the first half of 2020 was marked by several key achievements and milestones, solidifying ADMA's forward-looking growth strategy. Like others, we faced some challenges associated with COVID-19 and its impacts as we continue to navigate through these unprecedented times. Despite these challenges and our instituting ongoing remote work-from-home and no travel policies, the company's staff continue to forge ahead and chip away at achieving our stated goals and objectives. ADMA continues to make progress with its manufacturing, supply chain and commercial objectives. We are proud to be a growing company in the plasma products industry. We are proud to be a company that's on the front lines interacting with convalescent COVID-19 plasma donors and having a voice to affect change as a member of the COVID-19 Global Plasma Alliance. We are working on a number of early-stage development activities at the present time targeting COVID-19, including testing assays, as well as potential treatments with differentiated plasma-derived therapies. As we progress with these R&D activities, we will be sure to inform our stakeholders. We thank you, our shareholders, for your continued support and commitment as an important part of the ADMA Biologics team, assisting us to pursue forward-thinking research and development activities, with the promise and power of plasma-derived antibody products. Thank you. Now, I would like to review progress in the second quarter and some of our recent milestones and achievements. At the end of June, we announced the opening and first collections at our new plasma collection center. We have successfully submitted the accompanying biologics license application to receive US FDA approval for this center, which is anticipated for mid-2021. We expect to open the third US plasma collection center and commence construction on a fourth center by the end of this year as well. We have several new plasma collection centers identified that are in various stages of development to meet our stated objective of having 5 to 10 built over the next three to five years. The global demand for US-sourced plasma for further manufacturing continues to outpace the available supply. And these investments into the ADMA BioCenters business unit are anticipated to support ongoing production and growth into the future. As many of you are aware, during the second quarter, ADMA joined the COVID-19 Global Plasma Alliance, a plasma industry collaboration led by CSL and Takeda that was established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19. As an alliance member company, ADMA's wholly-owned subsidiary, ADMA BioCenters has been collecting and providing COVID-19 high-titer plasma to the Alliance from individuals who have recovered from the COVID-19 infection. We are truly grateful for all the donors who continue to do good for others and donate their plasma. We need many more donations as an industry and we encourage all US citizens to make a difference and donate your plasma. We are proud to be working together with these great companies to fight COVID-19 and provide a potential treatment for this highly infectious disease. The success of this alliance relies on the support of people across the globe to donate plasma. Even if you have not had COVID-19, your plasma is useful and needed by many patients. We encourage you to find a plasma center near you by visiting www.donatingplasma.org and donate your plasma today. Every donation makes a difference and patients are counting on all of us. Moving on now to revenue. Importantly, during the quarter, we continued to add new customers and prescribers for BIVIGAM and ASCENIV. ADMA's commercial team has continued to push ahead and understands that many of the patients who are prescribed BIVIGAM and ASCENIV will require the therapies potentially year-round. Thus, managing the finished goods supply chain is a top priority for us as a company. We are working hard to ensure that any patient who is prescribed BIVIGAM or ASCENIV has continued doses available to them. In a historically tight IG supply environment, which is anticipated to have additional forward-looking tightness in product market availability, ADMA must not lose sight of the fact that building brand loyalty and ensuring that our patients need not worry about whether they will have their IG supply next month or the month thereafter is of paramount importance for the long-term success of our business. We are a company committed to responsible inventory management and treat our prescribers, patients and distribution partners' needs as a top priority. As we continue the commercial rollouts of BIVIGAM and ASCENIV, as well as continue to promote the use of NABI-HB in the face of the logistic and engagement challenges due to COVID-19, our company's grassroots promotional efforts are starting to pay off. We've been setting the stage for building long-term brand loyalty and company awareness in a market that has been dominated by large players for decades. We are building a business one patient at a time. And for our shareholders who have watched companies like the former Baxalta, CSL and Grifols grow over the past 5, 10, 20 years, understand the growth and success that is afforded to companies that operate in compliance and place the care of their patients and staff as high priorities. We have set the stage with our production over the previous 12 months to be in a position to now supply the US market with what we believe to be a reliable and continuous supply of BIVIGAM, ASCENIV and NABI-HB, and we look forward to achieving significant growth over the next three to five years where we believe we can grow our business to $250 million or more in top-line annual revenue. For the first half of 2020, we generated total revenues of $18 million, reflecting a nearly 80% increase over the first half of 2019. This includes $7.8 million in total revenue for the second quarter of 2020. While the second quarter revenues were greater than any prior-year period by approximately 19%, they were lower compared to the first quarter of 2020 due to certain temporary, unforeseen delays related to COVID-19 which we experienced in June with our final GMP product release testing performed by certain third-party vendors. This means that while a few of our production batches were finished on schedule, we were unable to submit to the US Food and Drug Administration for lot release authorization because of certain specific delayed lab test results. These testing delays prevented ADMA from receiving FDA authorization to sell additional completed production batches during the second quarter. These delays were experienced during the latter part of the second quarter, which have been resolved during July. In response to these delays, and in partnership with the FDA, we rapidly identified and added additional release testing laboratories to our approved consortium listed in our drug approval documents. We believe that we have completely resolved this issue and we do not anticipate any additional testing or batch release delays going forward. As of mid-July, we began receiving FDA releases for several completed product batches with our new testing laboratories' data. As we'll be seeing in our second quarter 2020 10-Q, our finished goods inventory has increased 75% to $9.1 million since year-end December 31, 2019. This translates into having more product batches ready for commercial sale as soon as the testing results are received. These batches of our commercial product are anticipated to be sold during the second half of 2020 and forward, with attention being paid to manage supply to ensure the continuity of patient care and taking into consideration uncertainties due to the backdrop of COVID-19. Now, I want to highlight here that there has been no adverse impact on market demand for any of our products. Market demand for all of our plasma products remains strong in the market, and we expect considerable revenue growth for the forward-looking three to five-year period. It's important to keep in mind that this is our third full quarter of revenues for BIVIGAM and ASCENIV. Given the 7 to 12-month production timeline, we are just now beginning to tap into the IG product that was manufactured in the second half of 2019 post FDA approval, about one year ago. This is why we are confident that the second half of 2020 can be considerably stronger than the first half. And we remain on track to achieve our stated goal of generating in excess of $250 million in annual revenues within the next three to five years. During the quarter, we continued to make great strides implementing our multifaceted supply chain robustness strategy, designed to enhance visibility in manufacturing throughput as we continue the commercial rollout of BIVIGAM and ASCENIV. We also purchased and installed a new aseptic filling machine, Vanrx SA25 Workcell, and manufactured four conformance batches of BIVIGAM at an increased scale that will allow us to ultimately manufacture at twice the volume compared to the scale that is FDA approved and in place today. These important initiatives are designed to reduce operating costs, improve our overall margins, and provide for faster production cycle turnaround time, providing the company with increased control and independence from third-party vendors and contractors. We remain on track to submit the appropriate applications to the FDA during the second half of 2020 and into 2021 and expect to begin benefiting from our supply chain investments as early as mid-2021. As we progress and make these regulatory filings, we will report any material news as it develops to our shareholders. Like many other companies in the life science sector, we experienced our share of COVID-19 challenges during the second quarter. In addition to the delay and a speedy resolution of the final GMP product release testing that I mentioned earlier, we also experienced certain COVID-19 related impacts to other areas of our supply chain, as well as our commercial engagement efforts. As a result of past state and local shelter-in-place orders, we experienced lower-than-normal donor collections at our FDA approved plasma center during the second quarter. During this early part of the third quarter, we have already observed an increase in plasma collections compared to the second quarter in 2020. We also experienced delayed shipments of non-plasma raw materials, sourced plasma from our contracted third-party suppliers, as well as delays in deliveries of personal protective equipment, reagents and supplies used in the manufacture of our products. During the quarter, we observed certain impacts to our customer engagement initiatives, including our sales and medical affairs field forces experiencing difficulties communicating directly with physicians and other healthcare professionals and the cancellation or postponement of a number of key scientific and medical meetings, which further limited our ability to communicate with potential customers. We have implemented a comprehensive suite of virtual engagement initiatives. However, clinician engagement has been reduced due to the rapidly evolving COVID-19 priorities at many US medical centers. Lastly, we achieved an important milestone this quarter regarding the reimbursement of ADMA's novel polyclonal IVIG product, ASCENIV. During the second quarter, thanks to the dedicated efforts of our market access and commercial team, we secured reimbursement for ASCENIV under the temporary J code and have established an average selling price or ASP for the therapy. This published payment limit by CMS of $963.54 per gram for ASCENIV is the first step for a new IVIG product to receive coverage by Medicare as well as supports reimbursement efforts for outpatient use by third-party payers. We are very pleased with how rapidly our ASP for ASCENIV has been established and reimbursement through Medicare was achieved. We are currently able to provide our three FDA-approved immune globulins to patients across the country in the inpatient and outpatient settings. Congrats to the team, if you're listening, for achieving this great milestone. And with that, I'll turn the call now over to Brian Lenz, our CFO, to review the financials.

Thank you, Adam. Since we issued a press release earlier today outlining our second quarter 2020 financial results, I'll review some of the highlights. For the three months ended June 30, 2020, total revenues were $7.8 million compared to $6.6 million for the second quarter of 2019. This represents an increase of approximately $1.2 million or 19%. The favorable revenue realized during the second quarter of 2020 was primarily due to sales of BIVIGAM, ASCENIV and plasma-derived intermediate fractions compared to no sales from these products during the same prior year period. Recall, both ASCENIV and BIVIGAM were approved by the FDA in April and May of 2019, respectively, and the contract for certain plasma-derived intermediate fractions was executed in early 2020. Subsequent to these FDA approvals of ASCENIV and BIVIGAM, our Boca facility began the commercial production ramp up during the second half of 2019. As Adam mentioned earlier, our finished goods commercial inventory has increased by 75% from $5.2 million as of December 31, 2019 to $9.1 million as of June 30, 2020. Please keep in mind, in accordance with Generally Accepted Accounting Principles, the value of our inventory is stated at our cost. This increase reflects our stated manufacturing cycle time from the second half of 2019's commercial production ramp up and we look forward to now being in a good position with solid inventories to continue adding customers, distribution partners and prescribers over the coming quarters and potentially generating considerable increased revenue during the second half of 2020 compared to the first half of this year. Consolidated net loss for the three months ended June 30, 2020 was $20.2 million or $0.23 loss per basic and diluted share compared to a consolidated net loss of $13.2 million or $0.25 loss for basic and diluted share for the second quarter of 2019. For the six months ended June 30, 2020, total revenues were $18 million compared to $10.1 million for the six months ended June 30, 2019. This represents an increase of $7.9 million or nearly 80%. The increase in revenues was primarily attributable to sales of BIVIGAM, ASCENIV and plasma-derived intermediate fractions, none of which again were available for commercial sale during the same prior-year period. Consolidated net loss for the six months ended June 30, 2020 was $39.4 million or $0.49 loss per basic and diluted share compared to consolidated net loss of $26.3 million or $0.53 loss per basic and diluted share for the six months ended June 30, 2019. At June 30, 2020, ADMA had cash and cash equivalents of $75.8 million and accounts receivable of $6.5 million. This is compared to cash and cash equivalents of $26.8 million and accounts receivable of $3.5 million at December 31, 2019. ADMA's net working capital as of June 30, 2020 was $130.1 million compared to $71.8 million as of December 31, 2019.

Thank you, Brian. ADMA has made excellent progress during 2020 thus far on its key corporate priorities, including initiatives to strengthen our supply chain, which will greatly benefit the company over the long term by reducing operating costs, improving margins and shortening production cycle timelines. Given the unprecedented macro market conditions in the US and the COVID-19 effects being experienced by us and our third-party vendors and suppliers, we believe these effects are temporary and that our future is bright and ripe for growth. While we have experienced some variability during our first year of sales, especially since we are commercializing our products on the backdrop of the COVID-19 pandemic, we are highly confident that revenues for the second half of 2020 will be considerably higher than that of the first half. Most importantly, for our shareholders, we remain on track to achieve our stated goal of generating in excess of $250 million in annual revenues over the next three to five years. I want to assure all of our stakeholders that our fundamentals remain strong and that the demand for our immune globulin products remains robust. We remain deeply committed to successfully navigating the ongoing commercial rollouts for BIVIGAM and ASCENIV and bringing each product to patients with life-threatening immune deficiencies. To the patients receiving our products, you have mine and my team's entire commitment to work relentlessly to ensure you have your immune globulin available when you need it. You can count on ADMA Biologics as a reliable and committed provider of immune globulins. We extend our sincerest gratitude and commend the efforts of the entire ADMA Biologics team that continues to rise to the challenge of navigating the company through this burdensome period in order to ensure that the critical plasma-derived, antibody-rich products we produce are available over the long term and continuously for our patients and customers. I truly thank all of you. With that, we will now open up the call for your questions.

[Operator Instructions]. Our first question comes from the line of Anthony Petrone with Jefferies.

Hey, this is Zack on for Anthony. Can you just talk about how many batches were locked up and delayed due to FDA testing?

Sure, it was a handful. We're not really prepared to give specifics, Zack, but it was a few batches. Not very many. But what we can tell you is that, if you think about the way we produce our product, this is a drug that we had produced 7 to 12 months earlier. They were all ready to go. And unfortunately, due to COVID, we have a lab that's based overseas in the United Kingdom and, unfortunately, they were just unable to get test results to us. We've worked very, very rapidly with the FDA. We were really pleased that the issue is completely resolved now. We've resumed lot releases, and we are back in the regular lot release process.

Okay, that's helpful. And then, looking at the second half, how should we look at expenses going forward?

Brian?

Sure. So, as we previously mentioned, we manufactured four conformance lots. We've disclosed that it’s about a little over $6 million for those batches. I would say that there are some extraordinary items in the cost of sales. As we continue to grow the organization and grow the plasma operating centers, you would look at it pretty comparable to where we had the first six months of this year, excluding the conformance batches.

Okay. And then, batch testing on BIVIGAM, can you just give us an update on that?

Batch testing on BIVIGAM for releases or are you talking about the capacity expansion project?

The capacity expansion?

Sure. So, I think during the quarter, we produced some additional conformance batches. We are on schedule. As I said in my prepared remarks, we do have plans to submit applications for a number of our ongoing supply chain robustness activities, including the fill finish machine for all three of our products as well as the capacity expansion for BIVIGAM, taking it from the already FDA approved scale of 2,200 liters per plasma pool up to 4,400 liters. So, we're on track with the timing, and we will keep the shareholders and our analysts informed, but we're hopeful that we can have this on file with the agency before the end of this year and some of the applications into the first part of 2021.

And our next question comes from the line of Elliot Wilbur with Raymond James.

Just specifically following up on the actual filing process for the scale up. I presume that would qualify as a prior approval supplement and somewhere in the range of four to six months for final FDA approval. Is that correct?

That's correct, Elliot. I think the way to answer that question is we should be looking at this as if it's a standard prior approval supplement. We'll put that on file and then the FDA would have four to six months. But I'm optimistic that there are ways to expedite certain reviews with the FDA during this period. I think, should COVID-19 persist, maybe there are ways that we can work with the agency. They have been very collaborative with us, as noted by resolving some of our other problems, but I think looking at some of the nearest term potential tightness in IG supply, I think that there are mechanisms and maybe some levers we can pull to potentially expedite that. For budgeting, forecasting, and planning purposes, we are looking at this as that's correct, it is standard PAS, prior approval supplement, to amend our existing FDA-approved BLA to allow us to manufacture at that scale.

Okay. And then, with respect to ASCENIV, obviously, this is a very detailed sell. To some extent, that's kind of been hindered in the current environment. But just any anecdotes that you can offer in terms of a direct physician interaction detailing the product discussions with P&T committees, just trying to get a sense of sort of where you are kind of here in the early stages of that commercial launch?

Sure. I'll just kind of straight on and say, P&T committees, getting everybody that you need is definitely hard. With that being said, we've had a number of customer engagement meetings one-on-one at academic centers, regional medical centers, as well as in the outpatient setting for ASCENIV. I think that in light of the current environment and the current situation with the backdrop of COVID-19 and the increased awareness, if you will, and understanding that antibodies that are in immune globulin and that are naturally occurring antibodies are helpful when trying to manage, prevent and treat different types of infectious diseases. So, we certainly had a number of inquiries requesting information through our medical affairs department. We've got a full library of information that we can share depending upon the patient populations. As well as in the outpatient setting, we're seeing that there are certain clinicians out there who are looking at different risk factors that their patients have, looking at environmental risk factors. And if you've seen, Elliot, the asceniv.com website has been up for a number of months now. If you go through the asceniv.com, there are certain areas of information there that talk about the types of patients that may be at a higher risk or increased risk for having problems due to respiratory infections. And roughly 90% of patients who are on IVIG still have problems with certain chronic persistent recurrent infections. So, we're seeing some patients receiving authorization and third-party payer approval to switch from standard IG to ASCENIV and we're very hopeful that, with this recent announcement that we've received, a reimbursement price, if you will, of our ASP, plus 6% for Medicare, that this should continue. Our sales force is busy. I can't tell you that they're flying around the country, going to all the fancy medical meetings. Additionally, all of the wonderful symposia and tradeshow booths that we had designed and paid for and planned are being used, but we're keeping it all ready because we think we're going to come through this and be stronger as a country and as a global society, and we'll get the message out there. But we're doing it grassroots, Elliot. We're able to engage one doctor at a time, one treatment center at a time, and we feel that we are making progress.

I just want to ask you a follow-up question to one of your last points there with respect to the recent J code issuance. Ultimately, how important do you expect Medicare to be in terms of the ASCENIV book of business? And then, with the issuance of that code, and correct me if I'm wrong, that basically allows clinicians to essentially use the product without any sort of prior authorization in the Medicare setting. Is that correct?

I guess your first part of the question, there are a number of patients that receive IVIG who are on Medicare. What percentage of ASCENIV's business, it's important. Every patient is important to us with a drug like ASCENIV. With respect to payer, there are – to answer your question, the short answer is yes, you're correct. However, with immune globulin, typically, 90% of immune globulin starts, whether they're on label or in evidence-based use, they typically do require some type of prior authorization. Our sales force has been able to work hand-in-hand – and our medical affairs force provides any sort of papers in the literature and we're working hand-in-hand with selectors to achieve the prior authorization needed. But to answer your question, in theory, patients will now be able to receive ASCENIV if they have a prescription for intravenous immune globulins and the doctor feels that ASCENIV is the right product for their patient.

And then, just last question, with respect to COVID-19, there's been some investigator-initiated studies looking at standard IVIG. Curious if you've heard any anecdotes with respect to either further studies or any stories of success there and whether or not you've seen any utilization of ASCENIV in COVID-19 patients, given that there's a certain percentage that also tend to have a fairly high prevalence of RSV and other respiratory illnesses.

Sure. Great question, Elliot. Thank you. I've read the same data as most of you and it seems that, depending upon the dose, depending upon the time that immune globulin is added to the treatment armamentarium, if you will, there has been a trend. Some of the data is out of China, some of the data out of the US, but there has been a trend that patients seem to be doing better. There's a plethora of data in the literature to support the utilization of immune globulin to help manage these infections. Now, this is outside of the package insert labeling and ADMA does not have any ongoing trials looking at these uses. The way to answer your next question is I hear a lot of things from our sales force. I hear a lot of things from a lot of people. I don't think it's – I don't have a way to confirm what they're using ASCENIV for other than what people are telling me. The best way to answer your question is, our products are commercially available. There are other IVIG products that are commercially available, and I believe that a number of institutions around the country are deploying the use of immune globulin in the inpatient setting to manage patients with COVID-19. I think it's reasonable to assume that, if a clinician has the ability to prescribe one of the ADMA's FDA-approved products, they may. IVIG is used 50%, 60% in an evidence-based way. I believe that it's reasonable to assume that IVIG, including ADMA's products, based on availability, will be used in these hospitals. That’s the best way I can answer your question.

And our next question comes from the line of Ram Selvaraju with H.C. Wainwright.

So, a general question which had been on my mind for quite some time. I was wondering if you could comment on the implications for ADMA of the shift from the intravenously-administered immunoglobulin to subcutaneously-administered immunoglobulin and if you think that that might potentially present benefits or opportunity to ADMA. And also, specifically, if you could comment on the potential for ASCENIV in particular to be administered subcutaneously.

ADMA at the present time does not have any FDA-approved products that are administered through the subcutaneous route of administration. Our products are administered intravenously or with NABI-HB, intramuscularly. I think that we can debate till the cows come home about some of the benefits of giving immune globulin for certain patients intravenously compared to giving the benefits of immune globulin subcutaneously. With the patient population that ADMA has its labeled indications for, which are patients with primary immune deficiency, we believe that the IV route of administration certainly allows for rapid bioavailability of the antibody and it's been shown to work for 20, 30 years. We look at the data and we look out there and the subcutaneous route of administration certainly offers convenience. It certainly offers the ability for patients to dose themselves when it's convenient for them. And it certainly helps in the time of COVID with respect to having patients administer the IG themselves without the need to go to an infusion center. In ADMA's experience, we have been informed that a number of patients who are receiving BIVIGAM and/or ASCENIV in an infusion center, either connected with a hospital or a freestanding clinic, that the payers have been approving at-home IV administration. From our perspective, we don't see any impact. The last thing I'll say is that, when you look at the data – and I was just on a panel. It feels like just. But Elliot's not on the line anymore, but it was at the Raymond James conference. I was under the – at least the data that I've seen is that in order to achieve the same IgG trough levels between an intravenous product and a subcutaneous product, you require more infusion. There was a clinician on the panel with me at the Raymond James conference who gave what I thought was a staggering percentage of how much more product you need to administer. I look at subcutaneous as something that we could do in the future, but at the present time, our focus is on manufacturing our intravenous product, pushing forward our R&D efforts with respect to COVID-19, as well as expanding the label for ASCENIV at the opportune time, and focusing on building up our safety inventories to ensure a reliable, continuous supply of immune globulin to our patients.

Okay. Again, a couple of other minor detail things. I was wondering if you could just verify that the new filling line expense that contributed to the increase in R&D spending is a non-recurring item. And then, also, if you could specify what percentage of the 2Q revenue base came from intermediate fractions.

Sure. I can take this, Ram. The R&D, look, throughout the year, we're going to have various projects in R&D, but this should be the bulk of the expenses from this fill line. With regards to breaking out revenues, we look at BIVIGAM, ASCENIV, NABI-HB and our intermediate fractions as all part of our collective aggregate revenues and the total amount of revenues for those products. We do not break out our individual products separately.

But the intermediate fractions is probably a minor contributor, right, if we were to characterize qualitatively?

We previously announced in early 2020 that we entered into a long-term supply agreement with a third-party customer that we'll be selling intermediate fractions in several million dollars this year and then it would grow to $10 million to $15 million to $20 million over the next two to three years in annual growth. So, I would say it's a meaningful contributor. We just signed the agreement earlier this year, and we are seeing ongoing revenue increases.

As our production ramps, we're going to be obviously producing more of the plasma-derived intermediates for sale. We're looking forward to it.

Okay. And then, just one last one on the plasma collection volume. When do you anticipate that those could return to sort of "normalized levels?"

Well, that's a great question. If I could ask you one back, when do you think COVID-19 is going to be gone? I think that is the question that we're all asking. Look, ADMA has exposure to this market. We've got a center that's operating. As I mentioned in my prepared remarks, and I think Brian has said too, we have certainly seen a rebound, if you will, from the lows that were experienced during the second quarter already in the third quarter. So, we're doing better. We feel pretty good. I think the industry as a whole is feeling better. The government has made a decision on the unemployment additional stipend. There are still other things that have been changing around the country with respect to certain geographic regions opening up. Depending upon which of my friends that have older children that are going back to college, some are open and some aren't. I think that can also provide benefits. I think it's a gradual return over the next 12 to 18 months until we get back to something normal. With respect to ADMA, I want to reiterate that our supply contract is solid. We feel very confident and we continue to receive all the plasma that we anticipate receiving and purchasing under our agreement. Between the addition of us building new centers, our existing centers seeing rebounds and the fact that our contract is currently in good standing and our supplier is delivering plasma as agreed, we feel very good that we're able to weather this storm probably a little bit better than some of the other fractionators that may have a bigger exposure with respect to their collections.

And our next question comes from the line of Leland Gershell with Oppenheimer.

Just on the inventory line, you've been keeping that number pretty stable, $56 million now versus $53 million back at the end of the year and $52 million at the end of the first quarter. So, we expect overall inventories then to continue to remain stable or will those also go up as you make more immunoglobulin in addition to the fact that the finished product inventory obviously will continue to rise? How should we think about that relationship?

I'll give you a very short answer, but I'll let Brian give you some more detail. Go ahead, Brian.

We think the inventory is going to continue to increase now that we have entered into commercial scale ramp up since the second half of 2019. As you can see, the finished goods have increased by 75%, just from the beginning of the year. We are going to continue to collect more plasma as we're opening up more centers. We're also going to continue to buy plasma from our third-party vendors. I would expect the inventory to continue to grow as we expect revenues to continue to grow. Don't forget, in the beginning of the call and in our press release, we did say we're anticipating $250 million in revenues over the next three to five years. You need inventory to grow to meet those numbers. And we are doing that.

Just wondering if you could quantify in any way possible kind of the advantages with the new aseptic filling machine in terms of both expense and margins and also timelines to finish product? Any way you can quantify it? I know it won't be coming online until probably mid-next year, but just wanted to see if you could share any thoughts there?

I think I can take a stab at this, Brian. Leland, it's hard for me to give you exact numbers because we haven't really made that much in it yet. What I can tell you that attracted me to this machine itself is that it does not use destructive weight checks. For anybody who has been in the fill-finish industry and who understands how this process works, depending upon if there's a purge vessel, depending upon if there are other types of feeder pumps and areas that go into this, there are places throughout the fill-finish process that are inherent for loss. We're really looking at this from the standpoint of there's non-destructive weight checks. The device is state-of-the-art technology. We're looking at it – the internal estimates are to achieve about a 10% improvement to gross margins. There's no transportation costs. We don't have to hire the fancy FedEx custom critical truck and have all that insurance and pay all that money to drive the product to our third-party contract fill-finish provider and bring it in-house. We can also expedite, if you will, the production throughput process because we'll now have all of that control. We think that that will contribute to being able to turn our inventory into commercial product faster. All of these things can contribute, so hopefully that gives you some insights into this. I think 10% is a fair assessment, in addition, but I'm very hopeful. For the ADMA team listening in, I'm hopeful that they can make some magic here. We are very excited. IG is a scarce resource, and we want to make sure that we can maximize all of it in the vial to go to patients, not to go for losses.

Thank you. This does close today's question-and-answer session. I would like to turn the conference back over to Adam Grossman for any further remarks.

Sure. I just want to thank everybody for your continued confidence and support and understanding during this time. The company is really doing great. We're really proud of the work that we're doing. And again, please, please donate plasma. It's not lip service. The only way we're going to really save our fellow countrymen and family members is to donate plasma. So, thanks for your attention. Thanks for your support. We look forward to hopefully seeing you soon. Take care, everybody.

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program and you may all disconnect. Everyone, have a great day.